Alvotech (ICE:ALVO)
984.00
-41.00 (-4.00%)
At close: Oct 28, 2025
Alvotech Revenue
Alvotech had revenue of $173.34M USD in the quarter ending June 30, 2025, a decrease of -12.79%. This brings the company's revenue in the last twelve months to $562.48M, up 82.19% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$562.48M
Revenue Growth
+82.19%
P/S Ratio
4.48
Revenue / Employee
$555.81K
Employees
1,012
Market Cap
305.35B ISK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Marel | 250.20B |
| Hagar | 177.12B |
| Festi | 147.75B |
| Íslandsbanki | 62.96B |
| Arion banki | 61.68B |
| Brim hf. | 58.07B |
| Hampiðjan | 47.38B |
| Sildarvinnslan Hf. | 43.52B |
Alvotech News
- 8 days ago - Alvotech Announces Changes in Global Business Development and Commercial Operations Team - GlobeNewsWire
- 8 days ago - Alvotech Announces Changes in Global Business Development and Commercial Operations Team - GlobeNewsWire
- 15 days ago - Alvotech: Promising Vertically Integrated Biosimilar Platform - Seeking Alpha
- 23 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 24 days ago - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 5 weeks ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire